GSU start-up awarded NIH grant to aid in early liver disease detection

Inlighta Biosciences, a start-up company led by Jenny Yang, Regents' Professor of Chemistry at Georgia State University, has been awarded a National Institute of Health grant to accelerate development of a magnetic resonance imaging contrast agent to detect liver fibrosis, formation of scar tissue in the liver caused by alcoholic and non-alcoholic fatty liver disease, according to a press release.

Biopsy is the only way to identify liver fibrosis, an invasive procedure that often catches the disease only in later stages. Yang’s agent binds with collagen, a protein that is over-expressed as a result of fibrosis, alerting clinicians to the presence of early-stage disease using a non-invasive method. Imaging using her agent could help researchers identify regression of the disease during treatment, which could have major implications for treatment and new drug discovery.

The Centers for Disease Control and Prevention estimates that in 2017, more than 41,000 Americans died from chronic liver disease and cirrhosis. A 2015 National Survey on Drug Use and Health indicated 15.1 million adults ages 18 and older struggle with alcohol-use disorder, a number that is thought to be increasing during the pandemic. The largest and fastest-growing population at risk for developing fibrosis are individuals with nonalcoholic fatty liver disease, which is often associated with obesity and diabetes.

The research has been reviewed by the U.S. Food and Drug Administration, and may soon qualify for “fast-track and breakthrough” designation, which expedites the development and review of drugs and treatments for life-threatening illnesses.

The award, administered through the National Institute of Health’s National Institute on Alcohol Abuse and Alcoholism, will support Yang’s research through a Small Business Technology Transfer grant.

Yang says the funding fills a critical gap to get the research into clinical trials by supporting studies required to obtain an Investigational New Drug approval by the FDA. The first phase of the grant will fund $2 million over two years. An additional $4.5 million in second-phase funding will be awarded after important research milestones are achieved. Yang says she expects to be able to hit those benchmarks sooner than expected.

In pre-clinical models, her contrast agent identified liver disease resulting from a number of causes, including alcoholic liver disease, hepatitis C, hepatitis B, non-alcoholic fatty liver disease and autoimmune hepatitis.